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inpatient ($3,051 vs. $424, p< 0.0001), ER ($127 vs. $39, p< 0.0001), physician office 
($2,934 vs. $875, p< 0.0001), outpatient ($3,299 vs. $971, p< 0.0001), pharmacy ($610 
vs. $224, p< 0.0001) and total costs ($6,958 vs. $1,618, p< 0.0001) than the comparison 
cohort. ConClusions: Study results suggest that patients diagnosed with T2DM 
utilized more health resources and incurred four times higher costs compared to 
those without a T2DM diagnosis.
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objeCtives: The objective of the study was to estimate the excess costs associated 
with type 2 diabetes mellitus (T2DM) and diabetes-related complications in Japan 
through the use of a large claims database. Methods: We performed a retrospec-
tive cohort analysis using a large commercial claims database obtained from the 
Japan Medical Data Center Co., Ltd. (Tokyo, Japan). Data from the period between 
January 2005 and June 2012 were analyzed. Patients diagnosed with T2DM were 
identified using the International Classification of Diseases 10th revision (ICD-10) 
diagnosis codes E11–E14, with the month of initial diagnosis designated as the 
index month. Cost and health care utilization data from claims for outpatient, 
inpatient, and dispensing services during the study period were summarized to 
per-patient-per-month (PPPM) levels. Costs were calculated from the perspective of 
a public health care payer. Diabetes-related complications were identified through 
the occurrence of the following diseases after the index month and/or their associ-
ated treatment: retinopathy, nephropathy, neuropathy/extremity disease, ischemic 
heart disease, and cerebrovascular disease. Regression-adjusted medical costs 
associated with each health state of T2DM were estimated using a fixed-effects 
model. Results: A total of 8,063,139 PPPM records from 152,791 T2DM patients 
were identified and examined. The average follow-up duration per patient was 
52.8 months. The average incremental cost for T2DM was US$123 PPPM. The 
average incremental costs for diabetes-related complications were US$94 
(retinopathy without surgery), US$1,933 (retinopathy with surgery), US$17 (renal 
proteinuria), US$319 (renal failure), US$3,677 (dialysis), US$131 (neuropathy 
and/or extremity disease without surgery), US$4,498 (neuropathy and/or 
extremity disease with surgery), US$93 (ischemic heart disease without sur-
gery), US$13,280 (ischemic heart disease with surgery), US$56 (cerebrovascular 
disease with surgery), and US$2,605 (cerebrovascular disease with hospitaliza-
tion). ConClusions: These estimates of incremental medical expenditure in rela-
tion to health state may contribute to economic evaluations of various aspects 
of health care in Japan.
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objeCtives: To analyse the annual health care costs of patients with type 2 diabetes 
in Flanders from the perspective of the health care system and to assess the impact 
of comorbidities on total cost. Methods: Study participants were selected from 
the Independent Sickness Fund database on consumption of hypoglycemic agents 
and invited to participate in a clinical trial on diabetes education. Information on 
resource utilization during 12 months preceding inclusion was extracted from the 
database and combined with baseline clinical assessment data. Total health care 
costs consisted of costs paid by the public health insurance and patient co-payments 
and was analyzed as function of reported comorbidities through stepwise multiple 
regression. Results: 574 patients agreed to participate. Mean age was 64 years (35 - 
75) and type 2 diabetes was diagnosed since 7 years on average. 62% were men, 86% 
were treated with oral antidiabetics. 38% reported to have at least one comorbidity. 
30% were hospitalized in the study period. Hospitalizations accounted for 41% of 
the total cost, followed by outpatient prescription medications (22%) and physician 
consults (8%). The mean (95% CI) health care cost was € 4,522 (€ 3,799 to € 5,245). The 
mean annual cost of patients with no comorbidities was € 3,357 (€ 2,599 to € 4,116) 
and increased till € 4,750 (€ 3,511 to € 5,990) for those with one comorbidity (p= .001) 
and till € 7,303 (€ 3,909 to € 10,697) and € 9,868 (€ 4,685 to € 15,051) for those with two 
and three comorbidities respectively (p= .039 and. 057). Coronary heart disease was 
the main contributor to the cost variability (R2= 0.063, p= .000). ConClusions: Our 
study updates the knowledge on the actual annual cost of diabetes treatment in 
Flanders. Combination of clinical information and health insurance claims data 
allowed analysis based on the patient medical condition. The high marginal cost 
of people with comorbidities emphasises the importance of prevention for people 
diagnosed with type 2 diabetes.
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objeCtives: To estimate the multimorbity associated with diabetes mellitus 
type 2 and its relation to pharmaceutical cost in a primary health care set-
ting. Methods: Cross-sectional study during 2012. A health region of 5,150,540 
population was analysed to determine the diabetic individuals. 350,015 diabetic 
individuals were identified through clinical codes using the ICD-9-MC classifica-
tion and the 3M Clinical Risk Groups software. We analyzed the consumption of 
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objeCtives: The aim of this study is to assess for 2012 the cost of diabetes from a 
payer perspective, based on the French health insurance database and using two 
different approaches (top down versus bottom-up). Methods: Using information 
about 60 millions of individuals from the general scheme insurance database (85% 
of the French population), we developed algorithms to identify all people who 
received care for each of 56 groups of diseases or medical events or treatments, 
which are frequent, severe and/or costly. Algorithms have been applied to each 
patient. For diabetes, we used ICD-10 diagnoses for long-term chronic diseases, 
reimbursement for anti-diabetic drugs. Costs of all reimbursed expenditures (out-
patient/inpatient care, disability/sickness benefits) were extracted per individual. 
The top-down method allocated expenditure to each of the 56 diseases based 
on the average expenditure by disease calculated for individuals with only one 
disease. All expenditures were thereafter extrapolated to the whole population 
to fit national health account aggregates. For the bottom-up approach, diabetes 
expenditures were estimated by identifying finely in our database expenditure 
items which are partly or wholly directly related to diabetes according to expert 
judgment. Results: Based on the top-down approach, among the 146 billion 
euros of expenditures reimbursed by national health insurance (all insurance 
schemes) in 2012, 7. 5 billion (5%) are attributable directly to diabetes. Expenditures 
for chronic renal insufficiency and cardio-vascular disease, frequent diabetes com-
plications, have been assessed separately. Drugs and medical devices (3.8 billion € ) 
represents more than 50% of the diabetes expenditures, other outpatient care 
34% (2.5 billion), inpatient care 9% (700 millions) and disability/sickness benefits 
7% (500 millions). Based on our bottom-up, around 8 billion would be directly 
attributable to diabetes. ConClusions: Our study provides estimation of the 
cost of diabetes from a payer perspective, according to two different approaches 
but with concordant results.
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objeCtives: To determine the direct cost of health care technologies used for 
treatment of diffuse toxic goiter in Ukraine. Methods: We made the retrospec-
tive analysis of 52 patients’s medical records with DTG that were hospitalized to 
the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). The 
method of pharmacoeconomic analysis “cost of illness” was used to estimate the 
cost of health care for patients with DTG. We have made calculations of costs: the 
cost of laboratory analysis, the cost of instrumental analysis, the cost of drug treat-
ment, doctor’s consultations, costs of patient’s stay in hospital. While determining 
the direct costs of medical services in monetary terms we used the rates for medical 
services that were in Ternopil University Hospital. Results: The study found that 
among the patients there were 11 (21.15%) men and 41 (78.85%) women aged 20 to 
65 years (46.88±8.9). All patients have got to the hospital in stage of medication sub-
compensation. The average duration of stay in hospital for patients was 10.67±2.07 
days. The total cost of laboratory tests was EUR 1,555.53. The costs of instrumental 
methods of patients examination amounted EUR 204.25. The cost of consultations 
by specialists was EUR 285.97. In determining the amount of direct costs for medi-
cines we found that the cost of drug treatment of the underlying disease is EUR 
211.83, the cost of drug therapy of DTG complications is EUR 1,163.64. Total cost of 
patients stay in hospital was EUR 3,513.45. After calculation of all direct costs we 
determined that the total cost of DTG per patient is EUR 133.36 per course of treat-
ment. ConClusions: In the cost structure of health care provision for patients 
with diffuse toxic goiter the most significant costs were spent for laboratory tests 
and for patient’s stay in hospital. The presence of underlying disease complications 
significantly increases cost of drugs.
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objeCtives: To evaluate the economic burden and health care utilizations of Type 
2 diabetes mellitus (T2DM) among U.S. veteran patients. Methods: T2DM patients 
(International Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] 
diagnosis codes 250.x0, 250.x2) were identified using the U.S. Veterans Health 
Administration Medical SAS datasets (01OCT2008-31SEP2011). The first diagnosis 
date was defined as the index date. A comparison cohort of patients without a T2DM 
diagnosis but of the same age, region, gender and index year were identified and 
matched according to baseline Charlson Comorbidity Index scores, with a randomly 
chosen index date to minimize selection bias. Patients in both cohorts were required 
to be at least age 18 years, with 1-year continuous health plan enrollment pre- and 
post-index date. Baseline body mass index (BMI) and glycated hemoglobin (HbA1c) 
values and follow-up health care costs and utilizations were compared using 1: 
1 propensity score matching (PSM). Results: A total of 1,211,748 T2DM patients 
were identified for study. T2DM patients had significantly higher HbA1c (7.25 vs. 
5.78, p< 0.0001) and BMI (31.75 vs. 29.16, p< 0.0001) results during the baseline period. 
After 1: 1 PSM, each cohort included 323,962 patients, with well-balanced baseline 
demographic and clinical characteristics. A higher percentage of T2DM patients had 
inpatient admissions (8.65% vs. 1.58%, p< 0.0001), emergency room (ER) (13.12% vs. 
4.44%, p< 0.0001) and physician office visits (99.54% vs. 45.22%, p< 0.0001) and pre-
scription fills (84.55% vs. 45.43%, p< 0.0001). The T2DM cohort also incurred higher 
